Comparative Pharmacology
Head-to-head clinical analysis: CO GESIC versus PERCODAN DEMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO GESIC versus PERCODAN DEMI.
CO-GESIC vs PERCODAN-DEMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination